U.S. License Holder:
Argenx BV
Date of License:
June-20-2023
Last Update:
Dec-15-2024
FDA-Approved Indications
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with:
Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive;
Chronic inflammatory demyelinating polyneuropathy (CIDP).